XML 56 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statements of Income (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Net revenue $ 126,516us-gaap_SalesRevenueNet $ 177,235us-gaap_SalesRevenueNet
Operating expenses:    
Cost of revenue 33,737us-gaap_CostOfGoodsAndServicesSold 66,867us-gaap_CostOfGoodsAndServicesSold
Research and development 23,949us-gaap_ResearchAndDevelopmentExpense 31,096us-gaap_ResearchAndDevelopmentExpense
Selling, general and administrative 80,534us-gaap_SellingGeneralAndAdministrativeExpense 64,521us-gaap_SellingGeneralAndAdministrativeExpense
Total operating expenses 138,220us-gaap_CostsAndExpenses 162,484us-gaap_CostsAndExpenses
(Loss) income from operations (11,704)us-gaap_OperatingIncomeLoss 14,751us-gaap_OperatingIncomeLoss
Co-promotion and license income 8,388mdco_CoPromotionIncome 6,020mdco_CoPromotionIncome
Gain on remeasurement of equity investment 22,741us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain 0us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
Loss in equity investment (144)us-gaap_IncomeLossFromEquityMethodInvestments 0us-gaap_IncomeLossFromEquityMethodInvestments
Interest expense (8,607)us-gaap_InterestExpense (3,860)us-gaap_InterestExpense
Other income 109us-gaap_OtherNonoperatingIncomeExpense 179us-gaap_OtherNonoperatingIncomeExpense
Income before income taxes 10,783us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments 17,090us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Provision for income taxes (5,777)us-gaap_IncomeTaxExpenseBenefit (22,095)us-gaap_IncomeTaxExpenseBenefit
Income (loss) 5,006us-gaap_ProfitLoss (5,005)us-gaap_ProfitLoss
Net loss attributable to non-controlling interest 28us-gaap_NetIncomeLossAttributableToNoncontrollingInterest 9us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Net income (loss) attributable to The Medicines Company $ 5,034us-gaap_NetIncomeLoss $ (4,996)us-gaap_NetIncomeLoss
Basic (loss) income per common share attributable to The Medicines Company (USD per share) $ 0.08us-gaap_EarningsPerShareBasic $ (0.08)us-gaap_EarningsPerShareBasic
Diluted (loss) income per common share attributable to The Medicines Company (USD per share) $ 0.08us-gaap_EarningsPerShareDiluted $ (0.08)us-gaap_EarningsPerShareDiluted
Weighted average number of common shares outstanding:    
Basic (shares) 65,174us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 64,152us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Diluted (shares) 66,929us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 64,152us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding